Arcutis Biotherapeutics, Inc. (ARQT) is a Healthcare stock trading at $26.19 (as of 2026-06-18), with a market capitalization of $2.67B and a trailing P/E of -1219.0. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Arcutis Biotherapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing dermatology treatments. It is advancing topical candidates including ARQ-151 for plaque psoriasis and atopic dermatitis (Phase III completed), along with ARQ-154, ARQ-252, and ARQ-255 for other skin conditions.